Trial Profile
Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2019
Price :
$35
*
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 18 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 23 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Apr 2009 Actual initiation date changed from 1 April 2009 to 21 April 2009, as reported by Sanofi Pasteur media release.